{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T13:47:26Z","timestamp":1792849646346,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Oliver Krug for technical assistance and Antidoping Switzerland"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.mce.2017.01.040","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T03:00:17Z","timestamp":1485486017000},"page":"34-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Detection of SARMs in doping control analysis"],"prefix":"10.1016","volume":"464","author":[{"given":"Mario","family":"Thevis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Sch\u00e4nzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2017.01.040_bib1","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.bmc.2015.03.032","article-title":"Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I","volume":"23","author":"Aikawa","year":"2015","journal-title":"Bioorg Med. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2013.10.042","article-title":"A\u00a0novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate","volume":"720","author":"Akita","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mce.2017.01.040_bib3","doi-asserted-by":"crossref","first-page":"e0151860","DOI":"10.1371\/journal.pone.0151860","article-title":"Advantages and limitations of androgen receptor-based methods for detecting anabolic androgenic steroid abuse as performance enhancing drugs","volume":"11","author":"Bailey","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.mce.2017.01.040_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/gerona\/gls078","article-title":"The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men","volume":"68","author":"Basaria","year":"2013","journal-title":"J.\u00a0Gerontol. A Biol. Sci. Med. Sci."},{"key":"10.1016\/j.mce.2017.01.040_bib5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ncpendmet0120","article-title":"Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging","volume":"2","author":"Bhasin","year":"2006","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2017.01.040_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1471-2474-15-291","article-title":"Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization","volume":"15","author":"Blanque","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.mce.2017.01.040_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/156802606776173456","article-title":"Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential","volume":"6","author":"Cadilla","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/anatox\/35.9.594","article-title":"The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications","volume":"35","author":"Cadwallader","year":"2011","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.mce.2017.01.040_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0035-1552989","article-title":"Cell-based assays for screening androgen receptor ligands","volume":"33","author":"Campana","year":"2015","journal-title":"Semin. Reprod. Med."},{"key":"10.1016\/j.mce.2017.01.040_bib10","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1021\/jm401625b","article-title":"1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators","volume":"57","author":"Piatnitski Chekler","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib11","first-page":"162","article-title":"Development of selective androgen receptor modulators and their therapeutic applications","volume":"8","author":"Chen","year":"2002","journal-title":"Zhonghua Nan Ke Xue"},{"key":"10.1016\/j.mce.2017.01.040_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/mi.5.3.7","article-title":"Discovery and therapeutic promise of selective androgen receptor modulators","volume":"5","author":"Chen","year":"2005","journal-title":"Mol. Interv."},{"key":"10.1016\/j.mce.2017.01.040_bib13","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1517\/14740338.2015.1094052","article-title":"Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids","volume":"14","author":"Choi","year":"2015","journal-title":"Exp. Opin. Drug Saf."},{"key":"10.1016\/j.mce.2017.01.040_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/1008-682X.122339","article-title":"Selective androgen receptor modulators for the treatment of late onset male hypogonadism","volume":"16","author":"Coss","year":"2014","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.mce.2017.01.040_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/dta.1986","article-title":"Detection of LGD-4033 and its metabolites in athlete urine samples","volume":"9","author":"Cox","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.mce.2017.01.040_bib16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2013.03.003","article-title":"GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy","volume":"72","author":"Cozzoli","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mce.2017.01.040_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/SPC.0000000000000015","article-title":"Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer","volume":"7","author":"Dalton","year":"2013","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"10.1016\/j.mce.2017.01.040_bib18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1248\/bpb.b12-00885","article-title":"Mechanism of the tissue-specific action of the selective androgen receptor modulator S-101479","volume":"36","author":"Furuya","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.mce.2017.01.040_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.drudis.2007.01.003","article-title":"Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)","volume":"12","author":"Gao","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.mce.2017.01.040_bib20","article-title":"In\u00a0vitro metabolism study of a black market product containing SARM LGD-4033","author":"Geldof","year":"2016","journal-title":"Drug Test. Anal"},{"key":"10.1016\/j.mce.2017.01.040_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00216-010-4569-8","article-title":"Validation of a GC\/MS method for the detection of two quinolinone-derived selective androgen receptor modulators in doping control analysis","volume":"400","author":"Gerace","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00216-010-4569-8","article-title":"Validation of a GC\/MS method for the detection of two quinolinone-derived selective androgen receptor modulators in doping control analysis","volume":"400","author":"Gerace","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.forsciint.2011.07.014","article-title":"SARM-S4 and metabolites detection in sports drug testing: a case report","volume":"213","author":"Grata","year":"2011","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.mce.2017.01.040_bib24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/dta.372","article-title":"High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach","volume":"3","author":"Guddat","year":"2011","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.mce.2017.01.040_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/en.2008-0674","article-title":"Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception","volume":"150","author":"Jones","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2017.01.040_bib26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1248\/bpb.34.318","article-title":"(17alpha,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene -21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor","volume":"34","author":"Kanno","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.mce.2017.01.040_bib27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1248\/bpb.b13-00231","article-title":"Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression","volume":"36","author":"Kanno","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.mce.2017.01.040_bib28","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1021\/ja00118a001","article-title":"Mechanism of oxidative amine dealkylation of substituted N,N-Dimethylanilines by cytochrome P-450: application of isotope effect profiles","volume":"117","author":"Karki","year":"1995","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.mce.2017.01.040_bib29","first-page":"821","article-title":"Selective androgen receptor modulators for frailty and osteoporosis","volume":"8","author":"Kilbourne","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.mce.2017.01.040_bib30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/jpet.105.088344","article-title":"The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in\u00a0vivo disposition and activity of selective androgen receptor modulators","volume":"315","author":"Kim","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.mce.2017.01.040_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1255\/ejms.1328","article-title":"In\u00a0vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry","volume":"21","author":"Knoop","year":"2015","journal-title":"Eur. J. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jevs.2012.01.005","article-title":"Characterization of in\u00a0vitro synthesized equine metabolites of the selective androgen receptor modulators S24 and S4","volume":"32","author":"Krug","year":"2012","journal-title":"J.\u00a0Equine Vet. Sci."},{"key":"10.1016\/j.mce.2017.01.040_bib33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00228-014-1743-5","article-title":"Identification of black market products and potential doping agents in Germany 2010-2013","volume":"70","author":"Krug","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.mce.2017.01.040_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1255\/ejms.1415","article-title":"Identification of selected in\u00a0vitro-generated phase-I metabolites of the steroidal selective androgen receptor modulator MK-0773 for doping control purposes","volume":"22","author":"Lagojda","year":"2016","journal-title":"Eur. J. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib35","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/jm030336u","article-title":"Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators","volume":"47","author":"Marhefka","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/ml1002508","article-title":"Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140","volume":"2","author":"Miller","year":"2011","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.mce.2017.01.040_bib37","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1021\/jm900280m","article-title":"Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit","volume":"52","author":"Mohler","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.chroma.2013.03.006","article-title":"Use of ultra-high pressure liquid chromatography coupled to high resolution mass spectrometry for fast screening in high throughput doping control","volume":"1288","author":"Musenga","year":"2013","journal-title":"J.\u00a0Chromatogr. A"},{"key":"10.1016\/j.mce.2017.01.040_bib39","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1021\/jm300249m","article-title":"Discovery of diarylhydantoins as new selective androgen receptor modulators","volume":"55","author":"Nique","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib40","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1021\/jm300281x","article-title":"Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator","volume":"55","author":"Nique","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/1008-682X.122581","article-title":"Androgen effects on skeletal muscle: implications for the development and management of frailty","volume":"16","author":"O'Connell","year":"2014","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.mce.2017.01.040_bib42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12603-013-0335-x","article-title":"A\u00a0phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia","volume":"17","author":"Papanicolaou","year":"2013","journal-title":"J.\u00a0Nutr. Health Aging"},{"key":"10.1016\/j.mce.2017.01.040_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jsbmb.2007.11.001","article-title":"Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator","volume":"109","author":"Piu","year":"2008","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.mce.2017.01.040_bib44","series-title":"Critical Compilation of PKA Values for Pharmaceutical Substances","author":"Prankerd","year":"2007"},{"key":"10.1016\/j.mce.2017.01.040_bib45","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/acs.jmedchem.5b01168","article-title":"2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile: a transdermal selective androgen receptor modulator (SARM) for muscle atrophy","volume":"59","author":"Saeed","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/mas.21479","article-title":"Human sports drug testing by mass spectrometry","volume":"36","author":"Sch\u00e4nzer","year":"2017","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.mce.2017.01.040_bib47","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.1021\/jm901149c","article-title":"Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators","volume":"52","author":"Schlienger","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib48","doi-asserted-by":"crossref","first-page":"17054","DOI":"10.1074\/jbc.M109.099002","article-title":"Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology","volume":"285","author":"Schmidt","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1941738113502296","article-title":"Muscle changes in aging: understanding sarcopenia","volume":"6","author":"Siparsky","year":"2014","journal-title":"Sports Health"},{"key":"10.1016\/j.mce.2017.01.040_bib50","series-title":"31st Cologne Workshop on Dope Analysis","article-title":"In\u00a0vitro and in\u00a0vivo metabolism of RAD140, a novel nonsteroidal SARM","author":"Sobolevsky","year":"2013"},{"key":"10.1016\/j.mce.2017.01.040_bib51","series-title":"Recent Advances in Doping Analysis","article-title":"Metabolism Study of the Selective Androgen Receptor Modulator LGD-4033","author":"Sobolevsky","year":"2015"},{"key":"10.1016\/j.mce.2017.01.040_bib52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/fon.13.273","article-title":"Enobosarm (GTx-024, S-22): a potential treatment for cachexia","volume":"10","author":"Srinath","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.mce.2017.01.040_bib53","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/dta.1466","article-title":"Detection of the selective androgen receptor modulator S-4 (Andarine) in a doping control sample","volume":"5","author":"Starcevic","year":"2013","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.mce.2017.01.040_bib54","series-title":"Mass Spectrometry in Sports Drug Testing - Characterization of Prohibited Substances and Doping Control Analytical Assays","author":"Thevis","year":"2010"},{"key":"10.1016\/j.mce.2017.01.040_bib55","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jms.1438","article-title":"Mass spectrometry of selective androgen receptor modulators","volume":"43","author":"Thevis","year":"2008","journal-title":"J.\u00a0Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-540-79088-4_5","article-title":"Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators","volume":"195","author":"Thevis","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.mce.2017.01.040_bib57","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpba.2014.05.020","article-title":"Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls","volume":"101","author":"Thevis","year":"2014","journal-title":"J.\u00a0Pharm. Biomed. Anal."},{"key":"10.1016\/j.mce.2017.01.040_bib58","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/rcm.7470","article-title":"Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - potential implications for sports drug testing programs","volume":"30","author":"Thevis","year":"2016","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib59","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/rcm.2389","article-title":"Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes","volume":"20","author":"Thevis","year":"2006","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib60","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1002\/rcm.3247","article-title":"Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis","volume":"21","author":"Thevis","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib61","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/rcm.3637","article-title":"Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography\/electrospray ionization tandem mass spectrometry","volume":"22","author":"Thevis","year":"2008","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib62","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jms.1364","article-title":"Mass spectrometry of hydantoin-derived selective androgen receptor modulators","volume":"43","author":"Thevis","year":"2008","journal-title":"J.\u00a0Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1255\/ejms.917","article-title":"Screening for two selective androgen receptor modulators using gas chromatography-mass spectrometry in doping control analysis","volume":"14","author":"Thevis","year":"2008","journal-title":"Eur. J. Mass Spectrom. (Chichester, Eng."},{"key":"10.1016\/j.mce.2017.01.040_bib64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00216-008-1882-6","article-title":"Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS\/MS","volume":"391","author":"Thevis","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib65","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/dta.91","article-title":"Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product","volume":"1","author":"Thevis","year":"2009","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.mce.2017.01.040_bib66","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/rcm.3987","article-title":"Doping control analysis of emerging drugs in human plasma - identification of GW501516, S-107, JTV-519, and S-40503","volume":"23","author":"Thevis","year":"2009","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib67","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/dta.211","article-title":"Characterization of in\u00a0vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in\u00a0vivo comparison to post-administration canine urine specimens","volume":"2","author":"Thevis","year":"2010","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.mce.2017.01.040_bib68","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00216-011-4859-9","article-title":"Current role of LC-MS(\/MS) in doping control","volume":"401","author":"Thevis","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.mce.2017.01.040_bib69","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/rcm.5100","article-title":"Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls","volume":"25","author":"Thevis","year":"2011","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib70","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/rcm.6558","article-title":"Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105","volume":"27","author":"Thevis","year":"2013","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1255\/ejms.1236","article-title":"Liquid chromatography-high resolution\/high accuracy (tandem) mass spectrometry-based identification of in\u00a0vivo generated metabolites of the selective androgen receptor modulator ACP-105 for doping control purposes","volume":"20","author":"Thevis","year":"2014","journal-title":"Eur. J. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/dta.1769","article-title":"Annual banned-substance review: analytical approaches in human sports drug testing","volume":"7","author":"Thevis","year":"2015","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.mce.2017.01.040_bib73","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/rcm.7189","article-title":"Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in\u00a0vitro generated phase-I metabolites for human sports drug testing","volume":"29","author":"Thevis","year":"2015","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.mce.2017.01.040_bib74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/dta.1928","article-title":"Annual banned-substance review: analytical approaches in human sports drug testing","volume":"8","author":"Thevis","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.mce.2017.01.040_bib75","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10593-006-0142-y","article-title":"Basicity of 2-phenyl-5-R-1,3,4-oxadiazoles","volume":"42","author":"Trifonov","year":"2006","journal-title":"Chem. Hetero Comp."},{"key":"10.1016\/j.mce.2017.01.040_bib76","series-title":"The 2016 Prohibited List","author":"World Anti-Doping Agency","year":"2016"},{"key":"10.1016\/j.mce.2017.01.040_bib77","series-title":"Anti-doping Testing Figures\u00a0- Archive","author":"World Anti-Doping Agency","year":"2016"},{"key":"10.1016\/j.mce.2017.01.040_bib78","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/17460441.2013.741582","article-title":"Deciphering the selective androgen receptor modulators paradigm","volume":"8","author":"Zhang","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.mce.2017.01.040_bib79","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2217\/fon.09.106","article-title":"Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia","volume":"5","author":"Zilbermint","year":"2009","journal-title":"Future Oncol."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720717300539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720717300539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T10:35:13Z","timestamp":1529663713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720717300539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":79,"alternative-id":["S0303720717300539"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2017.01.040","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of SARMs in doping control analysis","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2017.01.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}